NYSE:ANVS

Annovis Bio (ANVS) Stock Price, News & Analysis

$12.76
+0.88 (+7.41%)
(As of 04/24/2024 ET)
Today's Range
$11.99
$13.65
50-Day Range
$8.47
$12.76
52-Week Range
$5.42
$22.49
Volume
489,991 shs
Average Volume
268,207 shs
Market Capitalization
$140.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.75

Annovis Bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
117.5% Upside
$27.75 Price Target
Short Interest
Bearish
13.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.35) to ($2.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.18 out of 5 stars

Medical Sector

727th out of 909 stocks

Pharmaceutical Preparations Industry

336th out of 423 stocks

ANVS stock logo

About Annovis Bio Stock (NYSE:ANVS)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

ANVS Stock Price History

ANVS Stock News Headlines

Annovis Bio Sees Unusually High Options Volume (NYSE:ANVS)
The #1 Biotech Stock to Have on Your Radar in 2024…
Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!
The #1 Biotech Stock to Have on Your Radar in 2024…
Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!
ANVS Jul 2024 30.000 call
ANVS Oct 2024 5.000 put
ANVS Apr 2024 20.000 call
See More Headlines
Receive ANVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
4/24/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.75
High Stock Price Target
$36.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+126.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-56,200,000.00
Pretax Margin
-74,496.43%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.73) per share

Miscellaneous

Free Float
6,794,000
Market Cap
$135.20 million
Optionable
Optionable
Beta
1.59
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Maria L. Maccecchini Ph.D. (Age 73)
    Founder, CEO, President & Executive Director
    Comp: $965.6k
  • Mr. Henry Hagopian III (Age 56)
    M.B.A., Chief Financial Officer
    Comp: $510.05k
  • Dr. Cheng Fang Ph.D.
    Senior Vice President of Research & Development
  • Ms. Eve M. Damiano M.S.
    RAC, Senior Vice President of Regulatory Operations
  • Ms. Melissa Gaines
    Senior Vice President of Clinical Operations

ANVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Annovis Bio stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANVS shares.
View ANVS analyst ratings
or view top-rated stocks.

What is Annovis Bio's stock price target for 2024?

4 Wall Street research analysts have issued 1-year price objectives for Annovis Bio's shares. Their ANVS share price targets range from $9.00 to $36.00. On average, they predict the company's share price to reach $27.75 in the next year. This suggests a possible upside of 117.5% from the stock's current price.
View analysts price targets for ANVS
or view top-rated stocks among Wall Street analysts.

How have ANVS shares performed in 2024?

Annovis Bio's stock was trading at $18.70 on January 1st, 2024. Since then, ANVS stock has decreased by 31.8% and is now trading at $12.76.
View the best growth stocks for 2024 here
.

Are investors shorting Annovis Bio?

Annovis Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,500,000 shares, an increase of 11.1% from the March 15th total of 1,350,000 shares. Based on an average daily volume of 268,500 shares, the short-interest ratio is currently 5.6 days.
View Annovis Bio's Short Interest
.

When is Annovis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ANVS earnings forecast
.

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) issued its earnings results on Friday, March, 29th. The company reported ($1.09) earnings per share for the quarter.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Annovis Bio IPO?

Annovis Bio (ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO.

How do I buy shares of Annovis Bio?

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ANVS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners